StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) company profile

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.11+0.88 (+0.93%)

Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –

About Kiniksa Pharmaceuticals International

Pharmaceutical Preparations, SIC 2834

Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for debilitating diseases with significant unmet medical need, particularly cardiovascular and autoinflammatory conditions. Its commercial product, ARCALYST, is an interleukin-1 alpha and beta cytokine trap approved in the United States to treat recurrent pericarditis, Cryopyrin-Associated Periodic Syndromes, and Deficiency of Interleukin-1 Receptor Antagonist. The company delivers ARCALYST to patients through a network of specialty pharmacies, while advancing investigational clinical candidates such as KPL-387 for recurrent pericarditis and preclinical programs like KPL-1161.

The company markets its approved therapy throughout the United States, utilizing a specialized internal salesforce. Beyond the United States, it holds worldwide rights to ARCALYST excluding the Middle East and North Africa, having granted development and commercialization rights in the Asia-Pacific territory excluding Japan to a regional partner. The company operates an internal facility to manufacture drug substance for research and early-stage development, while relying on third-party contract manufacturers for late-stage and commercial drug supply. Headquarter details are not stated in the text.

Summary of the business section of Kiniksa Pharmaceuticals International's latest annual report, written by StockData.

Company profile

Company

Legal name
Kiniksa Pharmaceuticals International, plc
Headquarters
London, United Kingdom
Address
105 Piccadilly, Second Floor W1J 7NJ
Phone
(781) 431-9100
Employees
366, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
KNSA
Exchange
Nasdaq
IPO date
May 24, 2018
Shares outstanding
157M, Oct 23, 2026
Public float
$1.11B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1730430
CUSIP
G52694109
FIGI
BBG00KT2KFX7
Share class FIGI
BBG00KT2KGM7
EIN
98-1795578

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Sanj K. PatelCHAIRMAN & CEO, Director1,602,803
John F. PaoliniCHIEF MEDICAL OFFICER114,048
Michael R. MegnaCHIEF ACCOUNTING OFFICER12,697
Ross MoatCHIEF OPERATING OFFICER10,294
Mark RagosaCHIEF FINANCIAL OFFICER20,854
Dhiraj H. MalkaniCHIEF STRATEGY OFFICER–
Eben TessariCHIEF STRATEGY OFFICER23,976
Barry D. QuartDirector12,745
Richard S. LevyDirector22,359
G. Bradley ColeDirector11,672
Bros. Advisors (GP) LLC BakerDirector123,820
Brothers Life Sciences LP BakerDirector2,745,259
Felix BakerDirector–
Julian BakerDirector158,117
Bros. Advisors Lp BakerDirector–
Kimberly J. PopovitsDirector15,345
Thomas MalleyDirector87,312
Tracey L. McCainDirector15,345
667, L.P.Director132,566

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$10.78M$28.44M$3.51M$233$125
FY2024$7.01M$8.70M$2.37M$112$91
FY2023$5.30M$6.80M$1.77M$99$92
FY2022$6.11M$8.73M$1.92M$85$89
FY2021$6.59M$579.47K$1.70M$67$99

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Sanj K. Patel
Chief Executive Officer and Chairman of the Board
$943.13K$3.80M$4.74M$1.28M$14.00K$10.78M+54%
John F. Paolini, M.D., Ph.D.
Executive Vice President and Chief Medical Officer
$585.09K$1.08M$1.36M$530.94K$14.00K$3.57M+49%
Eben Tessari
Executive Vice President and Chief Operating Officer
$586.46K$1.08M$1.36M$533.28K$5.87K$3.57M+54%
Ross Moat
Executive Vice President and Chief Commercial Officer
$586.27K$1.08M$1.36M$533.33K$77.78K$3.64M+40%
Mark Ragosa
Senior Vice President and Chief Financial Officer
$552.80K$978.10K$1.22M$516.71K$14.00K$3.28M+51%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 24, 2018
Offer price
$18.00
Securities offered
8,477,777
Gross proceeds
$152.60M
Exchange
Nasdaq
First trading day
May 24, 2018
First-day close
$19.47+8.2%
Lock-up ends (est.)
Nov 20, 2018

“The initial public offering price per share is $18.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 366 full-time employees, of which 351 were located within the United States and 15 were located outside of the United States.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jun 28, 2024DeregistrationTermination of SEC registration (Form 15)
Jun 28, 2024Name changeName changed from Kiniksa Pharmaceuticals, Ltd. to Kiniksa Pharmaceuticals International, plc
May 24, 2018IPOInitial public offering priced (424B4 prospectus)
May 14, 2018ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?